mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0001 |
mRNA |
NVP-BEZ235 |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
0.0001 |
mRNA |
selumetinib:PLX-4032 (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
0.0002 |
mRNA |
selumetinib:BRD-A02303741 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
0.0002 |
mRNA |
Crizotinib |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.0003 |
mRNA |
CIL41 |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
0.0003 |
mRNA |
OSI-906 |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
0.0003 |
mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
0.0004 |
mRNA |
Zebularine |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.0005 |
mRNA |
ruxolitinib |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.0005 |